EXCLUSIVE: How Avicanna Is Advancing Plant-Derived, Cannabinoid-Based Products
Regulation is among the factors inhibiting the flow of capital to cannabis innovation.
Institutions are afraid to invest, and “big pharma is not coming in as we would like to see happen.”
